Abstract:The VHL protein (pVHL) functions as a tumor suppressor by regulating the degradation or activation of protein substrates such as HIF1α and Akt. In human cancers harboring wild-type VHL, the aberrant downregulation of pVHL is frequently detected and critically contributes to tumor progression. However, the underlying mechanism by which the stability of pVHL is deregulated in these cancers remains elusive. Here, we identify cyclin-dependent kinase 1 (CDK1) and peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) as two previously uncharacterized regulators of pVHL in multiple types of human cancers harboring wild-type VHL including triple-negative breast cancer (TNBC). PIN1 and CDK1 cooperatively modulate the protein turnover of pVHL, thereby conferring tumor growth, chemotherapeutic resistance and metastasis both in vitro and in vivo. Mechanistically, CDK1 directly phosphorylates pVHL at Ser80, which primes the recognition of pVHL by PIN1. PIN1 then binds to phosphorylated pVHL and facilitates the recruitment of the E3 ligase WSB1, therefore targeting pVHL for ubiquitination and degradation. Furthermore, the genetic ablation or pharmacological inhibition of CDK1 by RO-3306 and PIN1 by all-trans retinoic acid (ATRA), the standard care for Acute Promyelocytic Leukemia could markedly suppress tumor growth, metastasis and sensitize cancer cells to chemotherapeutic drugs in a pVHL dependent manner. The histological analyses show that PIN1 and CDK1 are highly expressed in TNBC samples, which negatively correlate with the expression of pVHL. Taken together, our findings reveal the previous unrecognized tumor-promoting function of CDK1/PIN1 axis through destabilizing pVHL and provide the preclinical evidence that targeting CDK1/PIN1 is an appealing strategy in the treatment of multiple cancers with wild-type VHL.

VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway

High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells

VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis

VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation

VHL loss attracts immune cells to tumours

Inactivation Of Von Hippel-Lindau Increases Ovarian Cancer Cell Aggressiveness Through The Hif1 Alpha/Mir-210/Vmp1 Signaling Pathway

Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma

VHL Deficiency Augments Anthracycline Sensitivity of Clear Cell Renal Cell Carcinomas by Down-Regulating ALDH2

Vhl And Hypoxia Signaling: Beyond Hif In Cancer

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic response

PIN1 and CDK1 Cooperatively Govern Pvhl Stability and Suppressive Functions

CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma

Pvhl Acts As a Downstream Target of E2F1 to Suppress E2F1 Activity.

Loss of VGLL4 Suppresses Tumor PD-L1 Expression and Immune Evasion

Pvhl Negatively Regulates Antiviral Signaling by Targeting MAVS for Proteasomal Degradation.

VHLmissense Mutation Delineate Aggressive Clear Cell Renal Cell Carcinoma Subtype with Favorable Immunotherapeutic Response

VHL Ser65 Mutations Enhance HIF2α Signaling and Promote Epithelial-Mesenchymal Transition of Renal Cancer Cells

Oncolytic Vaccinia Virus Inhibits Human Hepatocellular Carcinoma Mhcc97-H Cell Proliferation Via Endoplasmic Reticulum Stress, Autophagy and Wnt Pathways

Multi-Omics Profiling to Assess Signaling Changes upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines

Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma

HIFalpha isoform specific activities drive cell-type specificity of VHL-associated oncogenesis